Alzamend Neuro Announces It Has Contracted With Altasciences To Conduct A Phase I Relative Bioavailability Study for AL001 For Dementia Related To Alzheimer’s Disease In September 2021
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric